Fibrocell Science to Present at 2nd Annual Regen Med Investor Day & BioCentury Future Leaders in the Biotech Industry Confere...
March 20 2014 - 5:30PM
Business Wire
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell
therapy company primarily focused on developing first-in-class
treatments for rare and serious skin and connective tissue diseases
with high unmet medical needs, today announced that Gregory Weaver,
senior vice president and chief financial officer of Fibrocell
Science, will present at the Alliance for Regenerative Medicine’s
(ARM) 2nd Annual Regen Med Investor Day at 4:00 p.m. EDT on
Wednesday, March 26, 2014 at the Metropolitan Club in New York, and
the BioCentury Future Leaders in the Biotech Industry conference at
10:30 a.m. EDT on Friday, March 28, 2014 at the Millennium Broadway
Hotel & Conference Center in New York. Mr. Weaver will discuss
the company’s autologous fibroblast technology, its therapeutic
candidates in development, and its collaboration with Intrexon
Corporation (NYSE: XON) to develop genetically-modified
personalized biologics.
A live webcast of the presentation at ARM’s Regen Med Investor
Day will be available on Fibrocell’s website at
http://www.fibrocellscience.com/investors/events-and-presentations/.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell
therapy company primarily focused on developing first-in-class
treatments for rare and serious skin and connective tissue diseases
with high unmet medical needs. Based on its proprietary autologous
fibroblast technology, Fibrocell is pursuing breakthrough medical
applications of azficel-T for restrictive burn scarring and vocal
cord scarring. The company’s collaboration with Intrexon
Corporation (NYSE: XON), a leader in synthetic biology, includes
using genetically-modified fibroblasts for treating rare and
serious skin and connective tissue diseases for which there are no
currently approved products. For additional information, visit
www.fibrocellscience.com.
Corporate:Fibrocell Science, Inc.Gregory Weaver, +1
484-713-6000SVP & Chief Financial
Officergweaver@fibrocellscience.comorInvestor Relations:S.A.
Noonan Communications, LLCSusan Noonan,
212-966-3650susan@sanoonan.com
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Fibrocell Science (NASDAQ:FCSC)
Historical Stock Chart
From Aug 2023 to Aug 2024